Mela Sciences CEO Dr. Joseph Gulfo tells MassDevice that the company plans to roll out its MelaFind skin cancer screening device next quarter, now that the device is out of regulatory limbo.
Dr. Joseph Gulfo, CEO of Mela Sciences (NSDQ:MELA), says the company plans to begin rolling out its MelaFind skin cancer detection system during the first quarter of 2012, after winning a hard-earned green-light from the FDA.
"I don't think we'll be 'selling,' in the classic sense of selling, for at least a year and a half," Gulfo told MassDevice. "Dermatologists want this system, so we don't need to 'sell' it.
"Since this is a new technology, our challenge will be incorporating it into the doctor's office," Gulfo said.
In what Mela Sciences is calling a "commercial development year," the company plans to place 200 MelaFind systems in the U.S. and 75 in Germany, working with doctors and patients to integrate the device into everyday care.
The company doesn't plan to seek insurance reimbursement until a few years down the line, Gulfo told us, adding that the systems cost $7,500 (including placement and training fees) and a patient use fee of $50.
When it comes time to distribute MelaFind on a large scale, the company will take the reins itself, instead of putting its flagship product in the hands of distributors.
The path to U.S. approval was a long one for Mela Sciences. More than two years, two panel reviews and one citizen's petition after it signed on for a 6-month FDA review, the company won FDA clearance for the U.S. market yesterday.
It's been a good season for the company, which also won CE Mark approval in the European Union for MelaFind in September.
Here's a look at some of the top regulatory stories for medical device companies this week.
Ulthera, which makes an ultrasound device designed to lift lax tissue on the neck and under the chin...
Dr. George Bakris, co-principal investigator in Medtronic's Symplicity-3 trial, says renal...
Delivering Medical Extrusions in 3-5 days - Fast & Flexible
A federal appeals court stays a ban on U.S. sales of Medtronic's CoreValve replacement heart valve...